Dot gov

Official websites use the Texas HHS logo.
The Texas HHS logo means this is an official website of Texas Health and Human Services.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

5. Revision History

StatusDateDescription
RevisionOct. 24, 2024

Texas DUR Board approved criteria:

  • Anti-diabetic Agents (oral)
  • Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder Medications
    • Glucagon-like Peptide 1 Receptor Agonists
  • Pramlintide
  • Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting (oral)
  • Substance P/Neurokinin 1 Receptor Antagonists
RevisionJuly 26, 2024

Texas DUR Board approved criteria:

  • Fluoroquinolones (oral)
  • Hepatitis C direct-acting antivirals
  • Immune globulins
  • Non-sedating antihistamines
  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Rifaximin (Xifaxan)
  • Sickle cell disease products
  • Skeletal muscle relaxants
RevisionJuly 1, 2024Revised Drug Use Compendia published
RevisionApril 26, 2024

Texas DUR Board approved criteria:

  • Benzodiazepines (oral, nasal, rectal)
  • Complement inhibitor and enzyme/ protein replacement therapy
  • Direct oral anticoagulants
  • Hydroxy-methylglutaryl coenzyme-A reductase inhibitors (statins)
  • Low molecular weight heparins
  • Nebulized bronchodilators
RevisionJan. 26, 2024

Texas DUR Board approved criteria:

  • Fentanyl
  • Gabapentin
  • Hydrocodone Bitartrate/ Hydrocodone Polistirex
  • Ivacaftor (Kalydeco) and Lumacaftor/Ivacaftor (Orkambi)
  • Topical Calcineurin Inhibitors
  • Tramadol
RevisionOct. 13, 2023

Texas DUR Board approved criteria:

  • Atypical Antipsychotics (long-Acting Injectable)
  • Atypical Antipsychotics (oral)
  • Exogenous Insulin Products
  • Nitazoxanide (Alinia)
  • Promethazine Use in Children Less than 2 Years of Age
  • Quetiapine (low dose)
RevisionJuly 21, 2023

Texas DUR Board approved criteria:

  • Acetylcholinesterase Inhibitors
  • Cyclooxygenase-2 Inhibitors
  • Histamine H2- Receptor Antagonists
  • Ketorolac (oral)
  • Leukotriene Receptor Antagonists
  • Mecasermin
  • Memantine
RevisionApril 28, 2023

Texas DUR Board approved criteria:

  • Aerosolized Agents - Metered-Dose Inhalers (MDIs): Anti-Cholinergic Drugs
  • Aerosolized Agents - Metered-Dose Inhalers (MDIs): Anti-Inflammatory Drugs
  • Aerosolized Agents - Metered-Dose Inhalers (MDIs): Beta2 Adrenergic Drugs (long-acting)
  • Aerosolized Agents - Metered-Dose Inhalers (MDIs): Beta2 Adrenergic Drugs (short-acting)
  • Anti-Depressants, Oral (other)
  • Anti-Depressants, Selective Serotonin Reuptake Inhibitors
RevisionJan. 20, 2023

Texas DUR Board approved criteria:

  • Angiotensin II Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Platelet Aggregation Inhibitors
  • Proton Pump Inhibitors
  • Sedative/Hypnotics
  • Serotonin 5-HT1B/1D Receptor Agonists
RevisionOct. 21, 2022

Texas DUR Board approved criteria:

  • Anti-Diabetic Agents (oral)
  • Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder Medications
  • Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
  • Pramlintide
  • Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting (oral)
  • Substance P/Neurokinin1 Receptor Antagonists
BaselineOct. 20, 2021Initial publication of content as the VDP Retrospective Drug Use Criteria Handbook.